Last Updated: October 1, 2026

Travere Company Profile

✉ Email this page to a colleague

« Back to Dashboard

What is the competitive landscape for TRAVERE

TRAVERE has one approved drug.

There are two US patents protecting TRAVERE drugs.

Summary for Travere

US Patents:	2
Tradenames:	1
Ingredients:	1
NDAs:	1

Drugs and US Patents for Travere

+ Get email alerts for changes to this table

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Travere	FILSPARI	sparsentan	TABLET;ORAL	216403-001	Feb 17, 2023		RX	Yes	No		⤷ Start Trial				⤷ Start Trial
Travere	FILSPARI	sparsentan	TABLET;ORAL	216403-002	Feb 17, 2023		RX	Yes	Yes	9,662,312	⤷ Start Trial				⤷ Start Trial
Travere	FILSPARI	sparsentan	TABLET;ORAL	216403-001	Feb 17, 2023		RX	Yes	No		⤷ Start Trial				⤷ Start Trial
Travere	FILSPARI	sparsentan	TABLET;ORAL	216403-002	Feb 17, 2023		RX	Yes	Yes	9,993,461	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

International Patents for Travere Drugs

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration
China	104107176	⤷ Start Trial
Luxembourg	C00347	⤷ Start Trial
Denmark	2732818	⤷ Start Trial
European Patent Office	2732818	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration

Supplementary Protection Certificates for Travere Drugs

Subscribe to access the full database, or Start Trial
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3222277	LUC00357	Luxembourg	⤷ Start Trial	PRODUCT NAME: SPARSENTAN OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; AUTHORISATION NUMBER AND DATE: EU/1/23/1788 20240423
3222277	122024000053	Germany	⤷ Start Trial	PRODUCT NAME: SPARSENTAN ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON; AUTHORISATION NO/DATE: EU/1/23/1788 20240419
3222277	24C1038	France	⤷ Start Trial	PRODUCT NAME: SPARSENTAN OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; REGISTRATION NO/DATE: EU/1/23/1788 20240423
3222277	202440030	Slovenia	⤷ Start Trial	PRODUCT NAME: SPARSENTAN OR ITS PHARMACEUTICALLY ACCEPTABLE SALT; NATIONAL AUTHORISATION NUMBER: EU/1/23/1788; DATE OF NATIONAL AUTHORISATION: 20240419; AUTHORITY FOR NATIONAL AUTHORISATION: EU
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Travere

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.